| Deler fremragende | 5,351,374 shares |
| Insideraktier | 1.232.224 shares |
| Insider ejerskab | 23,03 % |
| Total Insiders | 22 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Insiderhandelsdiagram
Aligos Therapeutics, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Lawrence Blatt Chief Executive Officer, Director - [D] [O] | 2.120.633 | 84.825 | |
| Leonid Beigelman President, Director - [D] [O] | 18.355 | 734 | |
| Lesley Ann Calhoun | 26.250 | ||
| Kathleen Sereda Glaub Director - [D] | 59.550 | 2.382 | |
| Peter Hirth Director - [D] | 59.549 | 2.382 | |
| Bridget A Martell | 30.000 | ||
| McClure Matthew W. Chief Medical Officer - [O] | 91.204 | 3.648 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Peter Moldt | 0 | ||
| Jack Nielsen | 0 | ||
|
A/S Novo
10% Owner -
|
2.614.563 | 104.583 | |
|
Carole Nuechterlein
Director, 10% Owner -
[D]
|
11.025.941 | 441.038 | |
| Quan Lucinda Y. See Remarks - [O] | 9.258 | 370 | |
|
Holding Ltd Roche
10% Owner -
|
11.025.941 | 441.038 | |
| James Paul Scopa Director - [D] | 183.083 | 7.323 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Symons Julian A. See Remarks - [O] | 394.064 | 15.763 | |
|
Versant Vantage I, L.P.
10% Owner -
|
862.444 | 34.498 | |
|
Versant Venture Capital VI, L.P.
10% Owner -
|
862.444 | 34.498 | |
|
Vivo Capital Fund VIII, L.P.
10% Owner -
|
430.372 | 17.215 | |
|
Vivo Capital Surplus Fund VIII, L.P.
10% Owner -
|
430.372 | 17.215 | |
|
Vivo Capital VIII, LLC
10% Owner -
|
430.372 | 17.215 | |
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
10% Owner -
|
1.906.191 | 76.248 | |
| Thomas Woiwode Director - [D] | 4.452 | 178 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALGS / Aligos Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALGS / Aligos Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-07 | 3 | ROCHE HOLDING LTD | ALGS | Common Stock, par value $0.0001 per share | I | 11.025.941 | ||||||||
| 2023-10-27 | 2023-10-25 | 4 | Nuechterlein Carole | ALGS | Common Stock | I | 0,7568 | 7.933.601 | 6.004 | 11.025.941 | ||||
| 2023-10-27 | 2023-10-25 | 4 | BLATT LAWRENCE | ALGS | Common Stock | D | 0,7568 | 610.277 | 462 | 1.847.575 | ||||
| 2023-10-27 | 2023-10-25 | 4 | Scopa James Paul | ALGS | Common Stock | D | 0,7568 | 183.083 | 139 | 183.083 | ||||
| 2022-05-06 | 3 | McClure Matthew W. | ALGS | Common Stock | I | 91.204 | ||||||||
| 2022-02-08 | 2022-02-04 | 4 | Quan Lucinda Y. | ALGS | Stock Option (Right to Buy) | D | 3,06 | 26.250 | 26.250 | |||||
| 2022-02-08 | 2022-02-04 | 4 | Quan Lucinda Y. | ALGS | Stock Option (Right to Buy) | D | 3,06 | 105.000 | 105.000 | |||||
| 2022-02-08 | 2022-02-04 | 4 | Calhoun Lesley Ann | ALGS | Stock Option (Right to Buy) | D | 3,06 | 26.250 | 26.250 | |||||
| 2022-02-08 | 2022-02-04 | 4 | Calhoun Lesley Ann | ALGS | Stock Option (Right to Buy) | D | 3,06 | 105.000 | 105.000 | |||||
| 2022-02-08 | 2022-02-04 | 4 | Symons Julian A. | ALGS | Stock Option (Right to Buy) | D | 3,06 | 26.250 | 26.250 | |||||
| 2022-02-08 | 2022-02-04 | 4 | Symons Julian A. | ALGS | Stock Option (Right to Buy) | D | 3,06 | 105.000 | 105.000 | |||||
| 2022-02-08 | 2022-02-04 | 4 | Beigelman Leonid | ALGS | Stock Option (Right to Buy) | D | 3,06 | 56.700 | 56.700 | |||||
| 2022-02-08 | 2022-02-04 | 4 | Beigelman Leonid | ALGS | Stock Option (Right to Buy) | D | 3,06 | 226.800 | 226.800 | |||||
| 2022-02-08 | 2022-02-04 | 4 | BLATT LAWRENCE | ALGS | Stock Option (Right to Buy) | D | 3,06 | 80.850 | 80.850 | |||||
| 2022-02-08 | 2022-02-04 | 4 | BLATT LAWRENCE | ALGS | Stock Option (Right to Buy) | D | 3,06 | 323.400 | 323.400 | |||||
| 2021-11-18 | 2021-11-16 | 4 | Martell Bridget A | ALGS | Stock Option (Right to Buy) | D | 16,52 | 30.000 | 30.000 | |||||
| 2021-06-17 | 2021-06-17 | 4 | Nielsen Jack | ALGS | Stock Option (Right to Buy) | D | 26,58 | 15.000 | 15.000 | |||||
| 2021-06-17 | 2021-06-17 | 4 | Woiwode Thomas | ALGS | Stock Option (Right to Buy) | D | 26,58 | 15.000 | 15.000 | |||||
| 2021-06-17 | 2021-06-17 | 4 | Hirth Peter | ALGS | Stock Option (Right to Buy) | D | 26,58 | 15.000 | 15.000 | |||||
| 2021-06-17 | 2021-06-17 | 4 | Nuechterlein Carole | ALGS | Stock Option (Right to Buy) | D | 26,58 | 15.000 | 15.000 | |||||
| 2021-06-15 | 2021-06-11 | 4 | Woiwode Thomas | ALGS | Common Stock | D | 2.226 | 4.452 | ||||||
| 2021-06-15 | 2021-06-11 | 4 | Woiwode Thomas | ALGS | Common Stock | I | -8.383 | 0 | ||||||
| 2021-06-15 | 2021-06-11 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 8.383 | 8.383 | ||||||
| 2021-06-15 | 2021-06-11 | 4 | Woiwode Thomas | ALGS | Common Stock | I | -9.719 | 0 | ||||||
| 2021-06-15 | 2021-06-11 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 9.719 | 9.719 | ||||||
| 2021-06-15 | 2021-06-11 | 4 | Woiwode Thomas | ALGS | Common Stock | I | -485.979 | 1.457.937 | ||||||
| 2021-04-28 | 2021-04-26 | 4 | Woiwode Thomas | ALGS | Common Stock | D | 2.226 | 2.226 | ||||||
| 2021-04-28 | 2021-04-26 | 4 | Woiwode Thomas | ALGS | Common Stock | I | -8.385 | 0 | ||||||
| 2021-04-28 | 2021-04-26 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 8.385 | 8.385 | ||||||
| 2021-04-28 | 2021-04-26 | 4 | Woiwode Thomas | ALGS | Common Stock | I | -9.720 | 0 | ||||||
| 2021-04-28 | 2021-04-26 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 9.720 | 9.720 | ||||||
| 2021-04-28 | 2021-04-26 | 4 | Woiwode Thomas | ALGS | Common Stock | I | -485.979 | 1.943.916 | ||||||
| 2021-04-27 | 2021-04-26 | 4 | Scopa James Paul | ALGS | Stock Option (Right to Buy) | D | 29,10 | 30.000 | 30.000 | |||||
| 2020-12-03 | 2020-12-01 | 4 | Symons Julian A. | ALGS | Stock Option (Right to Buy) | D | 16,18 | 200.000 | 200.000 | |||||
| 2020-12-03 | 2020-12-01 | 4 | BLATT LAWRENCE | ALGS | Stock Option (Right to Buy) | D | 16,18 | 450.000 | 450.000 | |||||
| 2020-12-03 | 2020-12-01 | 4 | Beigelman Leonid | ALGS | Stock Option (Right to Buy) | D | 16,18 | 300.000 | 300.000 | |||||
| 2020-12-03 | 2020-12-01 | 4 | Calhoun Lesley Ann | ALGS | Stock Option (Right to Buy) | D | 16,18 | 176.237 | 176.237 | |||||
| 2020-12-03 | 2020-12-01 | 4 | Quan Lucinda Y. | ALGS | Stock Option (Right to Buy) | D | 16,18 | 200.000 | 200.000 | |||||
| 2020-10-22 | 2020-10-20 | 4 | Novo A/S | ALGS | SERIES B -2 CONVERTIBLE PREFERRED STOCK | D | -241.219 | 0 | ||||||
| 2020-10-22 | 2020-10-20 | 4 | Novo A/S | ALGS | SERIES B -1 CONVERTIBLE PREFERRED STOCK | D | -563.851 | 0 | ||||||
| 2020-10-22 | 2020-10-20 | 4 | Novo A/S | ALGS | SERIES A CONVERTIBLE PREFERRED STOCK | D | -1.609.493 | 0 | ||||||
| 2020-10-22 | 2020-10-20 | 4 | Novo A/S | ALGS | COMMON STOCK | D | 15,0000 | 200.000 | 3.000 | 2.614.563 | ||||
| 2020-10-22 | 2020-10-20 | 4 | Novo A/S | ALGS | COMMON STOCK | D | 2.414.563 | 2.414.563 | ||||||
| 2020-10-22 | 2020-10-20 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | ALGS | Series B-2 convertible Preferred Stock | D | -571.143 | 0 | ||||||
| 2020-10-22 | 2020-10-20 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | ALGS | Series B-1 convertible Preferred Stock | D | -1.335.048 | 0 | ||||||
| 2020-10-22 | 2020-10-20 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | ALGS | Common Stock | D | 571.143 | 1.906.191 | ||||||
| 2020-10-22 | 2020-10-20 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | ALGS | Common Stock | D | 1.335.048 | 1.335.048 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Series B-2 Preferred Stock | I | -198.485 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Series B-2 Preferred Stock | D | -85.065 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Series B-1 Preferred Stock | I | -463.959 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Series B-1 Preferred Stock | D | -198.839 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Series A Preferred Stock | D | -2.145.991 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Common Stock | I | 15,0000 | 200.000 | 3.000 | 862.444 | ||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Common Stock | I | 198.485 | 662.444 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Common Stock | I | 463.959 | 463.959 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Common Stock | D | 85.065 | 2.429.895 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Common Stock | D | 198.839 | 2.344.830 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Versant Venture Capital VI, L.P. | ALGS | Common Stock | D | 2.145.991 | 2.145.991 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Surplus Fund VIII, L.P. | ALGS | Series B-2 Preferred Stock | I | -30.939 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. | ALGS | Series B-2 Preferred Stock | I | -224.054 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Surplus Fund VIII, L.P. | ALGS | Series B-1 Preferred Stock | I | -72.320 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. | ALGS | Series B-1 Preferred Stock | I | -523.726 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Surplus Fund VIII, L.P. | ALGS | Series A Preferred Stock | I | -260.380 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. | ALGS | Series A Preferred Stock | I | -1.885.611 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Surplus Fund VIII, L.P. | ALGS | Common Stock | I | 15,0000 | 66.733 | 1.001 | 430.372 | ||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. | ALGS | Common Stock | I | 15,0000 | 483.267 | 7.249 | 3.116.658 | ||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Surplus Fund VIII, L.P. | ALGS | Common Stock | I | 30.939 | 363.639 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Surplus Fund VIII, L.P. | ALGS | Common Stock | I | 72.320 | 332.700 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Surplus Fund VIII, L.P. | ALGS | Common Stock | I | 260.380 | 260.380 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. | ALGS | Common Stock | I | 224.054 | 2.633.391 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. | ALGS | Common Stock | I | 523.726 | 2.409.337 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. | ALGS | Common Stock | I | 1.885.611 | 1.885.611 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Series B-2 Preferred Stock | I | -198.485 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Series B-2 Preferred Stock | I | -85.065 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Series B-1 Preferred Stock | I | -463.959 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Series B-1 Preferred Stock | I | -198.839 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Series A Preferred Stock | I | -2.145.991 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 15,0000 | 200.000 | 3.000 | 862.444 | ||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 198.485 | 662.444 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 463.959 | 463.959 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 85.065 | 2.429.895 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 198.839 | 2.344.830 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Woiwode Thomas | ALGS | Common Stock | I | 2.145.991 | 2.145.991 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series B-2 Preferred Stock | I | -1.437 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series B-2 Preferred Stock | I | -1.437 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series B-2 Preferred Stock | I | -21.724 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series B-1 Preferred Stock | I | -3.359 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series B-1 Preferred Stock | I | -3.359 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series B-1 Preferred Stock | I | -50.781 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series A Preferred Stock | I | -13.559 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series A Preferred Stock | I | -13.559 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Series A Preferred Stock | I | -163.842 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 1.437 | 18.355 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 1.437 | 18.355 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 21.724 | 236.347 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 3.359 | 16.918 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 3.359 | 16.918 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 50.781 | 214.623 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 13.559 | 13.559 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 13.559 | 13.559 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Beigelman Leonid | ALGS | Common Stock | I | 163.842 | 163.842 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series B-2 Preferred Stock | I | -1.452 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series B-2 Preferred Stock | I | -1.452 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series B-2 Preferred Stock | I | -21.695 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series B-1 Preferred Stock | I | -3.394 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series B-1 Preferred Stock | I | -3.394 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series B-1 Preferred Stock | I | -50.712 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series A Preferred Stock | I | -13.671 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series A Preferred Stock | I | -13.671 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series A Preferred Stock | I | -122.601 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Series A Preferred Stock | I | -41.016 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 1.452 | 18.517 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 1.452 | 18.517 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 21.695 | 113.423 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 3.394 | 17.065 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 3.394 | 17.065 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 50.712 | 91.728 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 13.671 | 13.671 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 13.671 | 13.671 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 122.601 | 122.601 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | BLATT LAWRENCE | ALGS | Common Stock | I | 41.016 | 41.016 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Nuechterlein Carole | ALGS | Series B-2 Preferred Stock | I | -283.550 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Nuechterlein Carole | ALGS | Series B-1 Preferred Stock | I | -662.799 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Nuechterlein Carole | ALGS | Series A Preferred Stock | I | -2.145.991 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Nuechterlein Carole | ALGS | Common Stock | I | 283.550 | 3.092.340 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Nuechterlein Carole | ALGS | Common Stock | I | 662.799 | 2.808.790 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Nuechterlein Carole | ALGS | Common Stock | I | 2.145.991 | 2.145.991 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Quan Lucinda Y. | ALGS | Series B-2 Preferred Stock | I | -726 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Quan Lucinda Y. | ALGS | Series B-1 Preferred Stock | I | -1.697 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Quan Lucinda Y. | ALGS | Series A Preferred Stock | I | -6.835 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Quan Lucinda Y. | ALGS | Common Stock | I | 726 | 9.258 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Quan Lucinda Y. | ALGS | Common Stock | I | 1.697 | 8.532 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Quan Lucinda Y. | ALGS | Common Stock | I | 6.835 | 6.835 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Symons Julian A. | ALGS | Series B-2 Preferred Stock | D | -1.452 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Symons Julian A. | ALGS | Series B-1 Preferred Stock | D | -3.394 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Symons Julian A. | ALGS | Series A Preferred Stock | D | -13.671 | 0 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Symons Julian A. | ALGS | Common Stock | D | 1.452 | 394.064 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Symons Julian A. | ALGS | Common Stock | D | 3.394 | 392.612 | ||||||
| 2020-10-20 | 2020-10-20 | 4 | Symons Julian A. | ALGS | Common Stock | D | 13.671 | 389.218 | ||||||
| 2020-10-15 | 3 | Quan Lucinda Y. | ALGS | Common Stock | D | 375.547 | ||||||||
| 2020-10-15 | 3 | Symons Julian A. | ALGS | Common Stock | D | 375.547 | ||||||||
| 2020-10-15 | 3 | Beigelman Leonid | ALGS | Common Stock | D | 1.026.991 | ||||||||
| 2020-10-15 | 3 | Beigelman Leonid Trust | ALGS | Common Stock | I | 69.744 | ||||||||
| 2020-10-15 | 3 | Beigelman Leonid Trust | ALGS | Common Stock | I | 69.744 | ||||||||
| 2020-10-15 | 3 | Beigelman Leonid Trust | ALGS | Common Stock | I | 35.408 | ||||||||
| 2020-10-15 | 3 | Beigelman Leonid Trust | ALGS | Common Stock | I | 35.408 | ||||||||
| 2020-10-15 | 3 | BLATT LAWRENCE | ALGS | Common Stock | D | 1.237.298 | ||||||||
| 2020-10-15 | 3 | Hirth Peter | ALGS | Common Stock | D | 59.549 | ||||||||
| 2020-10-15 | 3 | Glaub Kathleen Sereda | ALGS | Common Stock | D | 59.550 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
